Role of the tumor suppressor KLF6 in prostate cancer

肿瘤抑制因子 KLF6 在前列腺癌中的作用

基本信息

项目摘要

DESCRIPTION (provided by applicant): Prostate cancer (PCa) is a leading cause of cancer death in men and diagnosed cases steadily increase. In the U.S., approximately 198,000 men will be diagnosed and 32,000 will die this year. Therefore, identification of causative genes and molecular pathways underlying prostate tumor initiation, growth and metastatic spread represents an urgent priority for the rationale development of improved diagnostics and preventative and therapeutic strategies. We demonstrated that the tumor suppressor KLF6, a member of the Kruppel-like family of zinc finger transcription factors which regulate growth-related signal transduction pathways, is frequently inactivated in human PCa. Two lines of evidence now suggest that KLF6 status can both define PCa susceptibility and long-term outcome. First, in a multi-institutional study of over 3,400 men, we have shown that a specific germline KLF6 SNP, regardless of family history of disease, increases lifetime risk of PCa. This SNP increases KLF6 gene alternative splicing to yield a biologically active, growth- promoting isoform, KLF6-SV1, that increases tumor cell proliferation, invasion, and in vivo tumor growth. Second, multiple gene expression studies link decreased KLF6 expression with tumor recurrence, poor clinical outcomes and chemotherapeutic resistance. Therefore, the hypothesis of this proposal is that loss of wild type KLF6 and/or increased expression of its alternatively spliced isoform KLF6-SV1, play a central role in the spectrum of PCa development, progression and metastasis. Our goals are to identify the clinicopathologic impact of KLF6 and KLF6-SV1 dysregulation on tumor behaviour and through genetically engineered in vivo models, identify the genetic and proteomic mechanisms underlying these biologic effects on PCa. Therefore, the specific aims of this proposal are: (1) Define the prevalence and clinicopathologic effects of altered KLF6 and KLF6-SV1 expression in PCa development and progression; (2) Investigate the effects of targeted KLF6 and KLF6-SV1 manipulation on prostate development, tumor susceptibility and malignant transformation, and; (3) Define the "KLF6-PCa interactome" - KLF6 and KLF6-SV1 protein-protein interactions critical to tumorigenesis and metastasis.
描述(由申请人提供):前列腺癌(PCa)是男性癌症死亡的主要原因,诊断病例稳步增加。在美国,今年将有大约198,000人被确诊,32,000人死亡。因此,鉴定前列腺肿瘤发生、生长和转移扩散的致病基因和分子途径是改进诊断和预防及治疗策略的基本原理发展的迫切优先事项。我们证明,肿瘤抑制因子KLF 6,一个成员的Kruppel样家族的锌指转录因子,调节生长相关的信号转导途径,经常在人类前列腺癌失活。两条证据表明KLF 6状态可以定义PCa的易感性和长期结果。首先,在一项对3,400多名男性进行的多机构研究中,我们已经证明,无论家族病史如何,特定的种系KLF 6 SNP都会增加PCa的终生风险。该SNP增加KLF 6基因选择性剪接以产生生物活性的、促进生长的同种型KLF 6-SV 1,其增加肿瘤细胞增殖、侵袭和体内肿瘤生长。其次,多基因表达研究将KLF 6表达降低与肿瘤复发、临床结果差和化疗耐药性联系起来。因此,该提议的假设是野生型KLF 6的缺失和/或其可变剪接同种型KLF 6-SV 1的表达增加在PCa发展、进展和转移的谱中起中心作用。我们的目标是确定KLF 6和KLF 6-SV 1失调对肿瘤行为的临床病理学影响,并通过基因工程体内模型,确定这些生物学效应对PCa的遗传和蛋白质组学机制。因此,本提案的具体目的是:(1)确定KLF 6和KLF 6-SV 1表达改变在PCa发展和进展中的患病率和临床病理学效应;(2)研究靶向KLF 6和KLF 6-SV 1操纵对前列腺发育、肿瘤易感性和恶性转化的影响;(3)明确KLF 6-PCa相互作用组-KLF 6和KLF 6-SV 1蛋白相互作用在肿瘤发生和转移中的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOHN A MARTIGNETTI其他文献

JOHN A MARTIGNETTI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOHN A MARTIGNETTI', 18)}}的其他基金

Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy
用于卵巢癌治疗的抗血管和细胞毒性纳米颗粒制剂
  • 批准号:
    10411413
  • 财政年份:
    2019
  • 资助金额:
    $ 32.86万
  • 项目类别:
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy
用于卵巢癌治疗的抗血管和细胞毒性纳米颗粒制剂
  • 批准号:
    9980812
  • 财政年份:
    2019
  • 资助金额:
    $ 32.86万
  • 项目类别:
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy
用于卵巢癌治疗的抗血管和细胞毒性纳米颗粒制剂
  • 批准号:
    10672982
  • 财政年份:
    2019
  • 资助金额:
    $ 32.86万
  • 项目类别:
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy
用于卵巢癌治疗的抗血管和细胞毒性纳米颗粒制剂
  • 批准号:
    10475624
  • 财政年份:
    2019
  • 资助金额:
    $ 32.86万
  • 项目类别:
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy
用于卵巢癌治疗的抗血管和细胞毒性纳米颗粒制剂
  • 批准号:
    10469185
  • 财政年份:
    2019
  • 资助金额:
    $ 32.86万
  • 项目类别:
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy
用于卵巢癌治疗的抗血管和细胞毒性纳米颗粒制剂
  • 批准号:
    10524135
  • 财政年份:
    2019
  • 资助金额:
    $ 32.86万
  • 项目类别:
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy
用于卵巢癌治疗的抗血管和细胞毒性纳米颗粒制剂
  • 批准号:
    10227030
  • 财政年份:
    2019
  • 资助金额:
    $ 32.86万
  • 项目类别:
Role of the tumor suppressor KLF6 in prostate cancer
肿瘤抑制因子 KLF6 在前列腺癌中的作用
  • 批准号:
    7439162
  • 财政年份:
    2007
  • 资助金额:
    $ 32.86万
  • 项目类别:
Role of the tumor suppressor KLF6 in prostate cancer
肿瘤抑制因子 KLF6 在前列腺癌中的作用
  • 批准号:
    7798240
  • 财政年份:
    2007
  • 资助金额:
    $ 32.86万
  • 项目类别:
Role of the tumor suppressor KLF6 in prostate cancer
肿瘤抑制因子 KLF6 在前列腺癌中的作用
  • 批准号:
    8051725
  • 财政年份:
    2007
  • 资助金额:
    $ 32.86万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 32.86万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了